Tripterygium wilfordii tablets in the treatment of active ankylosing spondylitis: a randomized double-blind, placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001193

Enrollment

Unknown

Registered

2011-02-22

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ankylosing spondylitis

Interventions

Treatment group: tripterygium wilfordii tablets

Control group:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Between the ages of 18 to 60 years old; 2. Meet the diagnostic criteria for ankylosing spondylitis. 3. BASDAI score >= 4; 4. Spinal pain VAS score >= 4.

Exclusion criteria

Exclusion criteria: (1) DMARDs in the 8 weeks to change drugs, including: hydroxychloroquine, sulfasalazine, methotrexate, thalidomide type or dose; (2) Changes in the NSAID class of 4 weeks and glucocorticoid type or dose; (3) Men and women of the future of family planning; (4) WBC3.0 mg/dl; (6) Abnormal biochemical values: ALT more than 2 times the normal figure; (7) Tripterygium wilfordii have been used without clinical effect; (8) Associated with other underlying diseases (such as cancer, active tuberculosis), the doctor that is not suitable for those who use Tripterygium wilfordii tablets; (9) Who are currently suffering from iritis; (10) Temperature >= 38 degree C; (11) Hepatitis B patients.

Design outcomes

Primary

Measure	Time frame
IgA;Liver function;ESR;blood routine test;CRP;	—

Countries

China

Contacts

Public ContactWei Ji

Weiweiji1103@yahoo.com.cn+86 25 86617141-31012

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026